Sonnet Biotherapeutics Holdings Inc represents a strong commitment to innovation and scientific excellence in the biotherapeutics industry. The company prioritizes the development of cutting-edge technologies and novel therapies to address unmet medical needs. Sonnet Biotherapeutics values a patient-centric approach, aiming to improve the lives of individuals through the advancement of their diverse pipeline of immunotherapies and targeted cancer treatments. The company demonstrates a corporate philosophy rooted in collaboration, integrity, and ethical practices. Sonnet Biotherapeutics Holdings Inc strives to establish itself as a leader in the biotechnology sector, driving positive change and transforming the future of healthcare.

Sonnet Biotherapeutics Holdings Inc is primarily present in the United States.

Sonnet Biotherapeutics Holdings Inc has achieved several significant milestones. The company successfully completed a merger with Chanticleer Holdings, Inc in December 2019, expanding its capabilities and expertise in the biopharmaceutical field. Sonnet Biotherapeutics also received a patent for its platform technology SON-101, which allows for the delivery of targeted cancer therapies. Additionally, the company successfully raised funds through private offerings to support its research and development initiatives. Sonnet Biotherapeutics continues to make advancements in its pipeline of innovative therapies, aiming to address various diseases and improve patient outcomes in the field of biotechnology.

Sonnet Biotherapeutics Holdings Inc is a biotechnology company with a rich history and background. Founded in [year], the company has been dedicated to developing innovative and transformative therapies to address unmet medical needs. Sonnet Biotherapeutics specializes in the discovery and development of fully human, targeted immunotherapeutics for cancer treatment. Leveraging its proprietary technology platform, the company focuses on creating next-generation biologic drugs that offer improved safety, efficacy, and accessibility. With a strong commitment to research and development, Sonnet Biotherapeutics aims to make significant advancements in the field of oncology and improve the lives of patients worldwide.

The main competitors of Sonnet Biotherapeutics Holdings Inc in the market include other biopharmaceutical companies operating in the same field such as Moderna Therapeutics, BioNTech SE, and Pfizer Inc. These companies also focus on the development and commercialization of innovative biotechnology products and therapeutics. Sonnet Biotherapeutics Holdings Inc competes within the industry by leveraging its unique technologies, strong research capabilities, and potential market advantages in order to differentiate itself and provide value to its shareholders and customers.

Sonnet Biotherapeutics Holdings Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Sonnet Biotherapeutics Holdings Inc is centered around developing and commercializing innovative, targeted biologic therapeutics to treat cancer and other diseases. They utilize their proprietary Fully Human Albumin Binding (FHAB) technology platform to design and engineer protein-based drugs that specifically target and bind to cancer cells, enabling precise and effective treatment with minimal side effects. The company focuses on advancing its pipeline of novel therapeutic candidates through preclinical and clinical studies, with the ultimate goal of providing improved treatment options and outcomes for patients in need. Sonnet Biotherapeutics Holdings Inc aims to make a significant impact in the field of oncology by revolutionizing the way cancer is treated.

Sonnet Biotherapeutics Holdings의 P/E 비율은 -0.01입니다.

Sonnet Biotherapeutics Holdings의 P/S 비율은 11.3입니다.

Sonnet Biotherapeutics Holdings에 대한 AlleAktien 품질 점수는 5/10입니다.

예상되는 Sonnet Biotherapeutics Holdings 매출은 38,250 USD입니다.

예상되는 Sonnet Biotherapeutics Holdings 이익은 -68.1 백만 USD입니다.

Sonnet Biotherapeutics Holdings Inc is a biopharmaceutical company that focuses on the discovery and development of novel immunotherapies targeting cancer cells. The company has developed a unique platform technology based on Sonnetins, which are protein engineering technologies that enable the production of fully human monoclonal antibodies with unique binding properties. The company's core business is the discovery of new cancer therapies through the use of the Sonnetins platform technology. There are two different divisions that the company pursues: internal and external research and development. Internal research efforts include the discovery and development of novel therapy candidates from Sonnet Bio, from preclinical to clinical phases. The company currently has several early clinical trials underway that have been approved by the FDA and aims to further expand its pipeline of cancer therapies. External research and development focuses on collaborating with other companies that wish to license or partner with the Sonnetins platform technology. Sonnet Bio is also actively working to protect its technology with other companies. Last year, Sonnet Bio collaborated with EnCode Bio, a leading provider of genome editing technologies, to develop a new class of immunotherapeutics with enhanced functionality. The company currently offers two product candidates. The first is Sonnet 155, a novel monoclonal antibody that recognizes the A2B receptor protein on cancer cells, which has been associated with a variety of cancer types. Preliminary clinical data suggest that Sonnet 155 has the potential to be used in the treatment of patients with solid tumors. The second product is Sonnet 126, a monoclonal antibody that recognizes and blocks the CD73 protein on cancer cells. Blocking CD73 is a promising strategy to stimulate the body's immune system to attack cancer cells. In addition to these products, Sonnet Bio has also maintained partnerships with other companies in various areas, including the development of genome editing technologies, diagnostics, and imaging diagnostics. Overall, Sonnet Bio's business model is focused on the discovery and development of cancer immunotherapies using its patented Sonnetins platform technology. The company has a diversified portfolio of therapy candidates and actively collaborates with other companies to expand its research and development activities.

Sonnet Biotherapeutics Holdings은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Sonnet Biotherapeutics Holdings의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Sonnet Biotherapeutics Holdings의 ISIN은 US83548R1059입니다.

Sonnet Biotherapeutics Holdings의 WKN은 A2P2NP입니다.

Sonnet Biotherapeutics Holdings의 티커는 SONN입니다.

지난 12개월 동안 Sonnet Biotherapeutics Holdings은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Sonnet Biotherapeutics Holdings은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Sonnet Biotherapeutics Holdings의 현재 배당 수익률은 입니다.

Sonnet Biotherapeutics Holdings은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Sonnet Biotherapeutics Holdings은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Sonnet Biotherapeutics Holdings은 '건강' 섹터에 속합니다.

Sonnet Biotherapeutics Holdings의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Sonnet Biotherapeutics Holdings는 0 USD를 배당금으로 지급했습니다.

Sonnet Biotherapeutics Holdings의 배당금은 USD에 지급됩니다.